Lupin gets 180-day exclusive U.S. launch for colonoscopy drug
First-to-file status on a $132.8M branded market gives Lupin six months of protected, high-margin sales.
— 2 earlier stories on Lupin Ltd. →What's new
- Lupin won final U.S. FDA approval for its generic Sutab tablets, a colonoscopy bowel prep drug.
- As exclusive first-to-file, the company gets 180 days of protected U.S. market access.
- The branded drug had estimated U.S. sales of $132.8M through March 2026.
Why this matters
First-to-file exclusivity is the most valuable prize in U.S. generics. It guarantees Lupin faces no competition for six months, allowing it to price near the branded level and capture outsized margins. For a company of Lupin's scale, the revenue is a rounding error; the margin impact is not.
What we're watching
- Lupin's U.S. launch pricing and market share take during the exclusivity window.
- Any patent challenges or regulatory stays that could shorten the 180-day period.
- The quarterly U.S. revenue contribution once sales begin.
The full read
Lupin has landed final U.S. FDA approval for a generic version of the colonoscopy prep drug Sutab. The real win is the exclusivity: as the exclusive first-to-file applicant, the company gets 180 days of protected market access with no generic rivals. The branded drug is not a blockbuster—it generated $132.8 million in U.S. sales through March 2026. For a company of Lupin's scale, that translates to roughly 1% of total revenue. But during the exclusivity window, the economics are different. With no competition, Lupin can price the generic near the branded level, turning a modest market into a high-margin product. Manufacturing will be handled at its Nagpur facility. This is a targeted pipeline win, adding a profitable six-month stream to the U.S. portfolio.
Questions answered
- What is the significance of the 'first-to-file' status?
- It grants Lupin 180 days of generic exclusivity in the U.S., during which no other generic competitor can launch. This protected period allows for higher pricing and margin capture on the $132.8M branded market.
- How big is the market for Sutab?
- The branded version of Sutab had estimated annual U.S. sales of $132.8 million for the period ending March 2026. The rationale notes this is a modest market relative to Lupin's overall size.
- Where will the generic be manufactured?
- The generic Sutab will be produced at Lupin's manufacturing facility in Nagpur, India.
- Does this approval materially change Lupin's revenue outlook?
- The revenue contribution is estimated at around 1% of the group's total annual revenue. The primary impact is profitability during the 180-day exclusivity phase, not the top line.
Story so far
All notes on LUPIN →- 29 May 2026 · 8:37 PM IST Lupin gets 180-day exclusive U.S. launch for colonoscopy drug
- 2d ago Lupin clears US FDA inspection for its Ankleshwar facility
- 8d ago Lupin wins its first drug approval in China